Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia

Anja Hviid Simonsen; Sanna-Kaisa Herukka; Niels Andreasen; Ines Baldeiras; Maria Bjerke; Kaj Blennow; Sebastiaan Engelborghs; Giovanni B Frisoni; Tomasz Gabryelewicz; Samantha Galluzzi; Ron Handels; Milica G Kramberger; Agnieszka Kulczyńska; Jose Luis Molinuevo; Barbara Mroczko; Agneta Nordberg; Catarina Resende Oliveira; Markus Otto; Juha O Rinne; Uroš Rot; Esen Saka; Hilkka Soininen; Hanne Struyfs; Silvia Suardi; Pieter Jelle Visser; Bengt Winblad; Henrik Zetterberg; Gunhild Waldemar

doi:10.1016/j.jalz.2016.09.008

Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia

Anja Hviid Simonsen, Sanna-Kaisa Herukka, Niels Andreasen, Ines Baldeiras, Maria Bjerke, Kaj Blennow, Sebastiaan Engelborghs, Giovanni B Frisoni, Tomasz Gabryelewicz, Samantha Galluzzi, Ron Handels, Milica G Kramberger, Agnieszka Kulczyńska, Jose Luis Molinuevo, Barbara Mroczko, Agneta Nordberg, Catarina Resende Oliveira, Markus Otto, Juha O Rinne, Uroš RotEsen Saka, Hilkka Soininen, Hanne Struyfs, Silvia Suardi, Pieter Jelle Visser, Bengt Winblad, Henrik Zetterberg, Gunhild Waldemar

Department of Clinical Medicine

75 Citations (Scopus)

54 Downloads (Pure)

Abstract

This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid-β1-42, tau, and phosphorylated tau in the diagnostic evaluation of patients with dementia. The recommendations were developed by a multidisciplinary working group based on the available evidence and consensus from focused discussions for (i) identification of Alzheimer's disease (AD) as the cause of dementia, (ii) prediction of rate of decline, (iii) cost-effectiveness, and (iv) interpretation of results. The working group found sufficient evidence to support a recommendation to use CSF AD biomarkers as a supplement to clinical evaluation, particularly in uncertain and atypical cases, to identify or exclude AD as the cause of dementia. Because of insufficient evidence, it was uncertain whether CSF AD biomarkers outperform imaging biomarkers. Operational recommendations for the interpretation of ambiguous CSF biomarker results were also provided.

Original language	English
Journal	Alzheimer's & Dementia
Volume	13
Issue number	3
Pages (from-to)	274-284
Number of pages	11
ISSN	1552-5260
DOIs	https://doi.org/10.1016/j.jalz.2016.09.008
Publication status	Published - 1 Mar 2017

Keywords

Alzheimer Disease/cerebrospinal fluid
Amyloid beta-Peptides/cerebrospinal fluid
Biomarkers/cerebrospinal fluid
Databases, Bibliographic/statistics & numerical data
Humans
Peptide Fragments/cerebrospinal fluid
tau Proteins/cerebrospinal fluid

Access to Document

10.1016/j.jalz.2016.09.008Licence: CC BY-NC-ND

Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementiaFinal published version, 795 KBLicence: CC BY-NC-ND

Cite this

Simonsen, A. H., Herukka, S.-K., Andreasen, N., Baldeiras, I., Bjerke, M., Blennow, K., Engelborghs, S., Frisoni, G. B., Gabryelewicz, T., Galluzzi, S., Handels, R., Kramberger, M. G., Kulczyńska, A., Molinuevo, J. L., Mroczko, B., Nordberg, A., Oliveira, C. R., Otto, M., Rinne, J. O., ... Waldemar, G. (2017). Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimer's & Dementia, 13(3), 274-284. https://doi.org/10.1016/j.jalz.2016.09.008

Simonsen, AH, Herukka, S-K, Andreasen, N, Baldeiras, I, Bjerke, M, Blennow, K, Engelborghs, S, Frisoni, GB, Gabryelewicz, T, Galluzzi, S, Handels, R, Kramberger, MG, Kulczyńska, A, Molinuevo, JL, Mroczko, B, Nordberg, A, Oliveira, CR, Otto, M, Rinne, JO, Rot, U, Saka, E, Soininen, H, Struyfs, H, Suardi, S, Visser, PJ, Winblad, B, Zetterberg, H & Waldemar, G 2017, 'Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia', Alzheimer's & Dementia, vol. 13, no. 3, pp. 274-284. https://doi.org/10.1016/j.jalz.2016.09.008

@article{daabec5f251142429ba6242a8898b8a2,

title = "Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia",

abstract = "This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid-β1-42, tau, and phosphorylated tau in the diagnostic evaluation of patients with dementia. The recommendations were developed by a multidisciplinary working group based on the available evidence and consensus from focused discussions for (i) identification of Alzheimer's disease (AD) as the cause of dementia, (ii) prediction of rate of decline, (iii) cost-effectiveness, and (iv) interpretation of results. The working group found sufficient evidence to support a recommendation to use CSF AD biomarkers as a supplement to clinical evaluation, particularly in uncertain and atypical cases, to identify or exclude AD as the cause of dementia. Because of insufficient evidence, it was uncertain whether CSF AD biomarkers outperform imaging biomarkers. Operational recommendations for the interpretation of ambiguous CSF biomarker results were also provided.",

keywords = "Alzheimer Disease/cerebrospinal fluid, Amyloid beta-Peptides/cerebrospinal fluid, Biomarkers/cerebrospinal fluid, Databases, Bibliographic/statistics & numerical data, Humans, Peptide Fragments/cerebrospinal fluid, tau Proteins/cerebrospinal fluid",

author = "Simonsen, {Anja Hviid} and Sanna-Kaisa Herukka and Niels Andreasen and Ines Baldeiras and Maria Bjerke and Kaj Blennow and Sebastiaan Engelborghs and Frisoni, {Giovanni B} and Tomasz Gabryelewicz and Samantha Galluzzi and Ron Handels and Kramberger, {Milica G} and Agnieszka Kulczy{\'n}ska and Molinuevo, {Jose Luis} and Barbara Mroczko and Agneta Nordberg and Oliveira, {Catarina Resende} and Markus Otto and Rinne, {Juha O} and Uro{\v s} Rot and Esen Saka and Hilkka Soininen and Hanne Struyfs and Silvia Suardi and Visser, {Pieter Jelle} and Bengt Winblad and Henrik Zetterberg and Gunhild Waldemar",

year = "2017",

month = mar,

day = "1",

doi = "10.1016/j.jalz.2016.09.008",

language = "English",

volume = "13",

pages = "274--284",

journal = "Alzheimer's & Dementia",

issn = "1552-5260",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia

AU - Simonsen, Anja Hviid

AU - Herukka, Sanna-Kaisa

AU - Andreasen, Niels

AU - Baldeiras, Ines

AU - Bjerke, Maria

AU - Blennow, Kaj

AU - Engelborghs, Sebastiaan

AU - Frisoni, Giovanni B

AU - Gabryelewicz, Tomasz

AU - Galluzzi, Samantha

AU - Handels, Ron

AU - Kramberger, Milica G

AU - Kulczyńska, Agnieszka

AU - Molinuevo, Jose Luis

AU - Mroczko, Barbara

AU - Nordberg, Agneta

AU - Oliveira, Catarina Resende

AU - Otto, Markus

AU - Rinne, Juha O

AU - Rot, Uroš

AU - Saka, Esen

AU - Soininen, Hilkka

AU - Struyfs, Hanne

AU - Suardi, Silvia

AU - Visser, Pieter Jelle

AU - Winblad, Bengt

AU - Zetterberg, Henrik

AU - Waldemar, Gunhild

PY - 2017/3/1

Y1 - 2017/3/1

N2 - This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid-β1-42, tau, and phosphorylated tau in the diagnostic evaluation of patients with dementia. The recommendations were developed by a multidisciplinary working group based on the available evidence and consensus from focused discussions for (i) identification of Alzheimer's disease (AD) as the cause of dementia, (ii) prediction of rate of decline, (iii) cost-effectiveness, and (iv) interpretation of results. The working group found sufficient evidence to support a recommendation to use CSF AD biomarkers as a supplement to clinical evaluation, particularly in uncertain and atypical cases, to identify or exclude AD as the cause of dementia. Because of insufficient evidence, it was uncertain whether CSF AD biomarkers outperform imaging biomarkers. Operational recommendations for the interpretation of ambiguous CSF biomarker results were also provided.

AB - This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid-β1-42, tau, and phosphorylated tau in the diagnostic evaluation of patients with dementia. The recommendations were developed by a multidisciplinary working group based on the available evidence and consensus from focused discussions for (i) identification of Alzheimer's disease (AD) as the cause of dementia, (ii) prediction of rate of decline, (iii) cost-effectiveness, and (iv) interpretation of results. The working group found sufficient evidence to support a recommendation to use CSF AD biomarkers as a supplement to clinical evaluation, particularly in uncertain and atypical cases, to identify or exclude AD as the cause of dementia. Because of insufficient evidence, it was uncertain whether CSF AD biomarkers outperform imaging biomarkers. Operational recommendations for the interpretation of ambiguous CSF biomarker results were also provided.

KW - Alzheimer Disease/cerebrospinal fluid

KW - Amyloid beta-Peptides/cerebrospinal fluid

KW - Biomarkers/cerebrospinal fluid

KW - Databases, Bibliographic/statistics & numerical data

KW - Humans

KW - Peptide Fragments/cerebrospinal fluid

KW - tau Proteins/cerebrospinal fluid

U2 - 10.1016/j.jalz.2016.09.008

DO - 10.1016/j.jalz.2016.09.008

M3 - Review

C2 - 28341065

SN - 1552-5260

VL - 13

SP - 274

EP - 284

JO - Alzheimer's & Dementia

JF - Alzheimer's & Dementia

IS - 3

ER -

Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia

Abstract

Keywords

Access to Document

Fingerprint

Cite this